Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer

Opinion
Video

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

Russ Conroy
June 23rd 2025
Article

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

Tim Cortese
June 17th 2025
Article

A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.